Source comparison
Comparison: Post-Surgical Recovery Peptides
BPC-157 VEGF upregulation, NF-κB pathway modulation, collagen synthesis Days 1–14 post-op (inflammation resolution phase) 250–500 mcg daily, subcutaneous or intramuscular Wound closure acceleration visible at 7–10 days; inflammation markers normalize by day 5
This comparison does not assign a generated winner or score.
- BPC-157
- VEGF upregulation, NF-κB pathway modulation, collagen synthesis
- Days 1–14 post-op (inflammation resolution phase)
- 250–500 mcg daily, subcutaneous or intramuscular
- Wound closure acceleration visible at 7–10 days; inflammation markers normalize by day 5
- Most consistent evidence for direct wound healing acceleration; well-tolerated with minimal reported adverse effects in observational use
- TB-500 (Thymosin Beta-4)
- Actin polymerization, cell migration, endothelial differentiation
- Days 3–21 post-op (tissue regeneration phase)
- 2–5 mg twice weekly, subcutaneous
- Scar tissue reduction and improved tissue pliability noted at 3–4 weeks
- Longer half-life allows less frequent dosing; effects on tendon and ligament repair particularly well-documented in preclinical models
- CJC-1295 + Ipamorelin
- Growth hormone pulse extension, IGF-1 upregulation, protein synthesis
- Days 1–30 post-op (catabolic recovery phase)
- 100–200 mcg each, 5 days per week, subcutaneous before bed
- Lean mass preservation measurable at 2–3 weeks; functional recovery markers improve by week 4
- Addresses systemic catabolic state rather than local wound healing; most effective when started within 72 hours of surgery to blunt initial protein breakdown
- MK-677 (Ibutamoren)
- Ghrelin receptor agonist, sustained GH and IGF-1 elevation
- Days 1–60 post-op (extended anabolic support)
- 12.5–25 mg daily, oral
- Appetite stimulation within 48 hours; anabolic effects measurable at 2–3 weeks
- Oral administration advantageous for patients unable to self-inject; appetite stimulation can be beneficial or problematic depending on surgical context